Putnam Inizio Advisory

Background

- The Health Technology Assessment Regulation (HTAR) in the European Union (EU), encompassing Joint Clinical Assessment (JCA) and Joint Scientific Consultation (JSC), introduces a unified framework for evaluating the clinical value of medicinal products (1)
- All new medicines will come under the scope of the regulation in January 2030, with the process already initiated for oncology drugs and advanced therapy medicinal products (ATMPs) (1)
- A structured population, intervention, comparator, outcome (PICO) approach is central to that framework (1,2)

Objective

• The objective of this research was to define strategic approaches for Global Biopharma/Biotech to ensure compliance with HTAR requirements and enable timely patient access to innovative drugs in the EU

Methods

- A review of current JCA/JSC requirements and guidelines, coupled with secondary desk research, was conducted to assess implications for internal Biopharma/Biotech processes and crossfunctional collaboration
- The potential for leveraging real-world evidence (RWE) to inform future PICO criteria and enhance stakeholder communication was also explored

Abbreviations:

ATMPs, Advanced Therapy Medicinal Products; CDP, Clinical Development Program; EC, European Commission; EGP, Evidence Generation Plan; EMA, European Medicines Agency; EU, European Union; **HTA**, Health Technology Assessment; **HTACG**, HTA Coordination Group; **HTAR**, HTA Regulation; **HTD**, Health Technology Developer; ITC, Indirect Treatment Comparison; JCA, Joint Clinical Assessment; JSC, Joint Scientific Advice; LR, literature review; MAA, Marketing Authorisation Application; **MS**, Member State; **PICO**, Population, Intervention, Comparator, Outcome; **PRO**, Patient-Reported Outcome; RWD, Real-World Data; RWE, Real-World Evidence; SAP, statistical analyses plan; SBU, Swedish Agency for Health Technology Assessment and Assessment of Social Services; **SLR**, Systematic Literature Review; **TLR**, Targeted Literature Review; **TLV**, The Swedish Dental and Pharmaceutical Benefits Agency

Conclusions

strategies while adapting internal team structures, roles, and planning processes.

References:

a EC. HTACG. 2024; 3. EUR-Lex. Regulation (EU) 2024/3169. 18 December 2024; 3. EUR-Lex. Commission Implementing Regulation (EU) 2024/3169. 18 December 2024; 3. EUR-Lex. Commission Implementing Regulation (EU) 2024/3169. 18 December 2024; 3. EUR-Lex. Commission (EC). HTACG. Procedural Guidance for JSC on Medicinal Products. 28 November 2024; 3. EUR-Lex. Commission Implementing Regulation (EU) 2024/3169. 18 December 2024; 3. EUR-Lex. Commission Implementing Regulation (EU) 2024/3169. 18 December 2024; 3. EUR-Lex. Commission Implementing Regulation (EU) 2024/3169. 18 December 2024; 3. EUR-Lex. Commission Implementing Regulation (EU) 2024/3169. 18 December 2024; 3. EUR-Lex. Commission (EU) 2024/3169. 18 December 2024; 3. EUR-Lex. Bec 2024/3169. 18 December 2024; 3. EUR-Lex. Bec 2024/3169 November 2024; 6. EC. HTACG. Annual Work Program 2025. V1.0. 28 November 2024; 7. Swedish Medical Products. 28 November 2024; 9. EC. HTACG. Guidance on outcomes for JCAs. 13 June 2024

Contact

Results

approach

generation

Strategic Implications of EU HTAR (JCA and JSC) for Global Biopharma and Biotech: Navigating Evolving Paradigms in Market Access


François C, PhD^{1,6}, Iyer S, PhD², Kuchenbecker^{3 U}, Dimassi M⁴, Kuciara A⁵, Rémuzat A¹ ¹ Putnam, Paris, France, ² Putnam, New York, USA, ³ Putnam, Berlin, Germany, ⁴Putnam, Tunis, Tunisia, ⁵Putnam, Kraków, Poland, ⁶Aix-Marseille University, Marseille, France

Joint scientific consultation (JSC)

• JSC, a voluntary process under the HTAR, that encourages early dialogue between health technology developers (HTDs) and Member States (MS), could play an essential role in shaping clinical study design that meets JCA evidence requirements (3,4)

• Early engagement—ideally before pivotal trial (Phase II/III)—is strongly recommended to align on key clinical aspects (PICO) and ensure pivotal trial generates robust data, particularly in areas where there is no established precedent in the field. Input on economic aspects to support national HTA submissions is also possible (4,5) • However, capacity for JSCs remains constrained, with only around 10 expected in 2025—5 to 7 for medicinal products and 1 to 3 for medical devices (6)

• Because only a few products are expected to be accepted for JSCs in the early years, companies should establish a fallback plan – such as seeking national HTA scientific advice – for instance, TLV and the SBU offer guidance on designing clinical trials to meet JCA and reimbursement requirements (7) – or conducting "mock" or "proxy" JSCs (e.g., via payer advisory boards) to anticipate likely research questions and PICOs



• While not binding, JCA reports will potentially shape nations, JCAs are expected to increasingly shape local evidence expectations and, ideally, reduce duplication. • It is crucial that companies leverage insights from upcoming evaluations to support internal teams and prepare for EU HTA submissions. • To prepare for JCA and meet demanding timelines and enable optimal patient access to innovative drugs, early cross-functional alignment is essential. Global biopharma/biotech should facilitate harmonization across regulatory, clinical, HEOR/RWE, and market access

U HTA procedure				
ossier paration	Dossier submission phase	Report drafting & finalisation phase		
0 days ~ 190 days				
Os				
late JCA ategy & ossier				
pdate LR & ITCs	5			
pdate C/RWD alyses				
ate trial				

requiring a streamlined internal process (Figure 1). • Health Technology Developer (HTD) will have only 100 days after final PICO scoping to submit the JCA dossier (60 days for accelerated procedure or type II variation) (8) and must justify any deviations from final PICOs (2)

- **PICO simulation** should guide the design of an **optimal clinical development plan**: major payer archetypes, and hold significant influence in the JCA process
 - timeline, and resource constraints
- evidence generation (**Table 1**)
- proposition and exploring key scenarios to maximize overall product value

Table 1. Evidence considerations: Strategy a			
Type of evidence	Relevance		
Systematic/target	 Develop a comprehen 		
literature review	(encompassing clinica		
(SLR/TLR)	adjustments (if require		
Patient-reported	 Include PROs in early- 		
outcomes (PROs)	within JCA scope (9), t		
Indirect treatment	• Plan ITCs against relev		
comparisons (ITC)	HTA requirements and		
	 This approach also ens 		
	submissions		
Real-world	Identify relevant RWD		
data/evidence	cleaning		
(RWD/RWE)	 Gain understanding of 		
	market needs		
	• Where trial data are lir		
	within ITCs		
Expert input	• Engage early with HTA		



Joint clinical assessment (JCA)

Early anticipation of PICO scoping is a critical step in aligning evidence generation for JCA with strategic objectives

• PICO simulation should reflect the perspectives of key markets that are **representative of the EU-27 Member States (MS)**, encompass

o PICO should be prioritized based on their relevance to strategic objectives and the feasibility of addressing them, considering technical,

• Anticipating PICO scoping is essential to identify potential evidence gaps early and proactively plan for tailored

• However, PICO should serve to refine – not dictate – the development strategy. Begin by defining an aspirational value

and planning components to meet JCA requirements

nsive, adaptable TLR (covering the disease and competitive landscape) and SLR al efficacy, safety, and patient-reported outcomes) to enable quick post-scope red)

-phase CDPs to capture patient-centric benefits in pivotal trial, since included to generate robust data aligned with expected PICO scenarios

vant comparators early—even for broader scopes—to align with multiple national d to allow for swift post-scope adjustments

sures that work done for JCA submission can be effectively leveraged in national

D sources early to accommodate multiple potential PICOs, with early data analysis

of local populations, treatment patterns (e.g., comparators in use), and evolving

imited, consider cautiously leveraging RWE to construct external comparator arms

TA experts, clinicians, and patients to inform evidence generation and PICO selection



All information is © 2025 Putnam LLC.

Find out more at putassoc.com